Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05198934
Study type Interventional
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email medinfo@amgen.com
Status Recruiting
Phase Phase 3
Start date April 19, 2022
Completion date January 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT01450319 - A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype Phase 2
Recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Completed NCT02903914 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT03253185 - A Study of SC-007 in Subjects With Advanced Cancer Phase 1
Recruiting NCT05585320 - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT00851045 - Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer Phase 2
Recruiting NCT04622423 - Advanced Therapies for Liver Metastases
Active, not recruiting NCT02955940 - An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Phase 2
Completed NCT02327078 - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Phase 1/Phase 2
Active, not recruiting NCT03314935 - A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT05379985 - Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS Phase 1
Completed NCT00165854 - Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02646748 - Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Phase 1
Not yet recruiting NCT02005913 - A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence N/A
Recruiting NCT04256707 - Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Phase 1/Phase 2
Recruiting NCT04792684 - Collection of Samples USOPTIVAL Study
Completed NCT00483080 - Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) Phase 2
Completed NCT03811652 - A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00977613 - Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients N/A